1,1,2,2,3,3,4,4,5-Nonafluoro-5,6,6-tris(trifluoromethyl)cyclohexane | 73196-05-1

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代烷
• 英文名称: 1,1,2,2,3,3,4,4,5-Nonafluoro-5,6,6-tris(trifluoromethyl)cyclohexane
• CAS: 73196-05-1
• 化学式: C₉F₁₈
• 分子量: 450.07
• InChiKey: SIJZIPMRLFRVHV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  27
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  18

文献信息

• MEDICINAL PREPARATION
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP1787661A1

  公开（公告）日：2007-05-23

  A pharmaceutical preparation has a ligand structure specifically recognizing a target site and an amphiphilic compound having a hydrophobic or amphiphilic group. The pharmaceutical preparation employs an amphiphilic compound of specific structure obtained by introducing a chained hydrophilic group with an appropriate flexibility, and thus becomes a fine particle suited for drug targeting. The pharmaceutical preparation is expected to give a prolonged pharmacological effect. A particulate preparation exhibiting a remarkable site targeting property can be formed. Further, according to the selection of matrix forming material, the drug releasing property can be controlled.

  一种药物制剂具有特异性识别靶位点的配体结构和具有疏水或两性亲和性基团的两性化合物。该药物制剂采用通过引入具有适当柔韧性的链状亲水基团获得的特定结构的两性化合物，因此成为适用于药物靶向的细颗粒。 预计该药物制剂将产生持久的药理效应。可以形成具有显著靶向性能的颗粒制剂。此外，根据基质形成材料的选择，可以控制药物释放性能。
• NANOEMULSIONS AND USE THEREOF AS CONTRAST AGENTS
  申请人：GUERBET

  公开号：US20140234223A1

  公开（公告）日：2014-08-21

  The invention relates to an oil-in-water nanoemulsion for MRI, including: an aqueous phase, a fluorinated phase including at least one fluorinated oil, a surfactant at the interface between the aqueous and fluorinated phases, the surfactant comprising: at least one amphiphilic targeting ligand, at least one amphiphilic lipid, and at least one diblock or triblock fluorophilic compound, as well as to the use thereof as a contrast agent.

  这项发明涉及一种用于磁共振成像的油包水纳米乳液，包括： 水相， 含有至少一种氟化油的氟化相， 位于水相和氟化相之间的表面活性剂，所述表面活性剂包括： 至少一种两性靶向配体， 至少一种两性脂质，以及 至少一种二嵌段或三嵌段亲氟化合物， 以及将其用作对比剂的用途。
• [EN] PHOTOSENSITIZER PARTICLES FOR MEDICAL IMAGING AND/OR PHOTODYNAMIC THERAPY<br/>[FR] PARTICULES DE PHOTOSENSIBILISATEUR DESTINÉES À L'IMAGERIE MÉDICALE ET/OU À LA THÉRAPIE PHOTODYNAMIQUE
  申请人：DCB USA LLC

  公开号：WO2014189796A1

  公开（公告）日：2014-11-27

  Photosensitizer particle contrast agents are suitable for medical imaging and/or photodynamic therapy. The photosensitizer particle contrast agent has a shell and a core encased by the shell. The shell consists essentially of multiple photosensitizer conjugates. Each photosensitizer conjugate consists of a photosensitizer and at least one biodegradable polymer covalently bound to the photosensitizer. The core has an echogenic contrast-enhancing material loaded therein. The photosensitizer of at least one of the multiple photosensitizer conjugates has a magnetic contrast-enhancing agent, e.g., a paramagnetic ion, chelated thereto. Methods for medical imaging use imaging compositions containing the photosensitizer particle contrast agents.

  光敏剂颗粒对比剂适用于医学成像和/或光动力疗法。光敏剂颗粒对比剂具有一个被壳包裹的壳和核心。壳主要由多个光敏剂结合物组成。每个光敏剂结合物由光敏剂和至少一个与光敏剂共价结合的可生物降解聚合物组成。核心中装载有增强超声对比的材料。多个光敏剂结合物中至少一个的光敏剂具有磁性增强对比剂，例如，螯合到其中的顺磁离子。用于医学成像的方法使用含有光敏剂颗粒对比剂的成像组合物。
• COMPOUNDS FOR THE DIAGNOSIS OF DISEASES ASSOCIATED WITH VCAM EXPRESSION
  申请人：Port Marc

  公开号：US20110200533A1

  公开（公告）日：2011-08-18

  The present invention relates to a compound of the following general formula (I): Signal-Linker-Peptide (I) in which: -Signal represents a signal entity; -Linker, which may or may not be present, represents a chemical bond, and -Peptide represents a peptide comprising a VCAM-targeting peptide, the VCAM-targeting peptide being chosen from the peptides of formula below and the functional equivalents thereof: a) X1-X2-X3-X4-X5-X6-X7-X8-X9 (1) (SEQ ID No. 1) where X1 is absent or chosen from cysteine and methionine; X2 chosen from asparagine and glutamine; X3 chosen from asparagine and glutamine; X4 chosen from serine and threonine; X5 chosen from lysine, arginine, histidine and ornithine; X6 chosen from serine and threonine; X7 chosen from histidine, arginine and lysine; X8 chosen from threonine and serine; X9 is absent or chosen from cysteine and methionine; preferably, the peptide CNNSKSHTC (SEQ ID No. 2) and the peptide NNSKSHT (SEQ ID No. 3); b) X10-X11-X12-X13-X14-X15-X16-X17-X18 (2) (SEQ ID No. 4) with X10 chosen from cysteine and methionine; X11 chosen from methionine and cysteine; X12 chosen from lysine, arginine and alanine; X13 chosen from threonine and serine; X14 chosen from aspartic acid and glutamic acid; X15 chosen from threonine and serine; X16 chosen from arginine, alanine and lysine; X17 chosen from leucine, isoleucine and valine; X18 chosen from cysteine and methionine; preferably, the peptide CMKTDTRLC (SEQ ID No. 5); and the pharmaceutically acceptable salts of these compounds of a) or of b).

  本发明涉及以下一般式(I)的化合物：Signal-Linker-Peptide (I)其中：- Signal代表信号实体；- Linker，可以存在也可以不存在，代表化学键；- Peptide代表包含VCAM靶向肽的肽，所述VCAM靶向肽从以下式的肽中选择，以及其功能等效物：a) X1-X2-X3-X4-X5-X6-X7-X8-X9 (1) (序列号1)，其中X1不存在或从半胱氨酸和蛋氨酸中选择；X2从天冬氨酸和谷氨酸中选择；X3从天冬氨酸和谷氨酸中选择；X4从丝氨酸和苏氨酸中选择；X5从赖氨酸、精氨酸、组氨酸和鸟氨酸中选择；X6从丝氨酸和苏氨酸中选择；X7从组氨酸、精氨酸和赖氨酸中选择；X8从苏氨酸和丝氨酸中选择；X9不存在或从半胱氨酸和蛋氨酸中选择；优选的肽为CNNSKSHTC (序列号2)和NNSKSHT (序列号3)；b) X10-X11-X12-X13-X14-X15-X16-X17-X18 (2) (序列号4)，其中X10从半胱氨酸和蛋氨酸中选择；X11从蛋氨酸和半胱氨酸中选择；X12从赖氨酸、精氨酸和丙氨酸中选择；X13从苏氨酸和丝氨酸中选择；X14从天冬氨酸和谷氨酸中选择；X15从苏氨酸和丝氨酸中选择；X16从精氨酸、丙氨酸和赖氨酸中选择；X17从亮氨酸、异亮氨酸和缬氨酸中选择；X18从半胱氨酸和蛋氨酸中选择；优选的肽为CMKTDTRLC (序列号5)；以及a)或b)中的这些化合物的药用盐。
• CONTRAST AGENTS FOR MYOCARDIUM PERFUSION IMAGING
  申请人：Edwards Scott D.

  公开号：US20070140973A1

  公开（公告）日：2007-06-21

  The present invention is directed, in part, to compounds and methods for diagnostic imaging, comprising administering to a patient a contrast agent which has an overall negative charge.

  本发明在一定程度上涉及化合物和用于诊断成像的方法，包括向患者施用总体带有负电荷的造影剂。